The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.

The fact that you can vaccinate a child at 5 years of age and find lymphoid B cells and antibodies specific for this vaccination 70 years later remains an immunologic enigma. It has never been determined how these long-lived memory B cells are maintained and whether they are protected by storage in a special niche. We report that, whereas blood and spleen compartments present similar frequencies of IgG(+) cells, antismallpox memory B cells are specifically enriched in the spleen where they account for 0.24% of all IgG(+) cells (ie, 10-20 million cells) more than 30 years after vaccination. They represent, in contrast, only 0.07% of circulating IgG(+) B cells in blood (ie, 50-100,000 cells). An analysis of patients either splenectomized or rituximab-treated confirmed that the spleen is a major reservoir for long-lived memory B cells. No significant correlation was observed between the abundance of these cells in blood and serum titers of antivaccinia virus antibodies in this study, including in the contrasted cases of B cell-depleting treatments. Altogether, these data provide evidence that in humans, the two arms of B-cell memory--long-lived memory B cells and plasma cells--have specific anatomic distributions--spleen and bone marrow--and homeostatic regulation.

[1]  M. Stegall,et al.  The Effect of Desensitization Protocols on Human Splenic B‐Cell Populations In Vivo , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  M. Slifka Immunological memory to viral infection: Commentary , 2004 .

[3]  C. Berek,et al.  Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. , 2005, Blood.

[4]  L. Klareskog,et al.  Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. , 2007, Clinical immunology.

[5]  G. Sutter,et al.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. , 1991, The Journal of general virology.

[6]  Sandeep Kumar Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara , 2000 .

[7]  Andreas Radbruch,et al.  Survival of long-lived plasma cells is independent of antigen. , 1998, International immunology.

[8]  X. Mariette,et al.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production , 2006, Annals of the rheumatic diseases.

[9]  O. Farges,et al.  Ex vivo perfusion of human spleens maintains clearing and processing functions. , 2006, Blood.

[10]  Andreas Radbruch,et al.  Lifetime of plasma cells in the bone marrow , 1997, Nature.

[11]  Andreas Radbruch,et al.  Adaptation of humoral memory , 2006, Immunological reviews.

[12]  S Miltenyi,et al.  Correlation analysis between frequencies of circulating antigen‐specific IgG‐bearing memory B cells and serum titers of antigen‐specific IgG , 1999, European journal of immunology.

[13]  Kenneth G. C. Smith,et al.  Competence and competition: the challenge of becoming a long-lived plasma cell , 2006, Nature Reviews Immunology.

[14]  R. Pabst,et al.  The bone marrow: a nest for migratory memory T cells. , 2005, Trends in immunology.

[15]  H. Ochs,et al.  Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  G. McFadden,et al.  Smallpox: anything to declare? , 2002, Nature Reviews Immunology.

[17]  M. Cooper,et al.  Memory B lymphocytes migrate to bone marrow in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Slifka Immunological memory to viral infection. , 2004, Current opinion in immunology.

[19]  C. Kneitz,et al.  Effective B cell depletion with rituximab in the treatment of autoimmune diseases. , 2002, Immunobiology.

[20]  R. Purcell,et al.  Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[21]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[22]  Luis Villarreal,et al.  Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination 1 , 2003, The Journal of Immunology.

[23]  Antonio Lanzavecchia,et al.  Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells , 2002, Science.

[24]  R. Zinkernagel On natural and artificial vaccinations. , 2003, Annual review of immunology.

[25]  R. Ahmed,et al.  Humoral immunity due to long-lived plasma cells. , 1998, Immunity.

[26]  K. Rajewsky,et al.  Memory B-cell persistence is independent of persisting immunizing antigen , 2000, Nature.

[27]  R. Ahmed,et al.  Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. , 2004, Journal of immunological methods.

[28]  J. Baars,et al.  Rituximab treatment results in impaired secondary humoral immune responsiveness. , 2002, Blood.

[29]  M. Frosch,et al.  Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. , 2001, Vaccine.

[30]  S. Hansen,et al.  Duration of antiviral immunity after smallpox vaccination , 2003, Nature Medicine.

[31]  K. Rajewsky,et al.  Maintenance of B-cell memory by long-lived cells generated from proliferating precursors , 1990, Nature.

[32]  Sandra K. Martin,et al.  Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. , 2004, The Journal of infectious diseases.